PTGX - CIK 0001377121
Protagonist Therapeutics, Inc trades as PTGX and has a market capitalization of $6.80 B, making it the #1171 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $46.02M, down 89.4% from the prior year and net income of -$130.15M. This page tracks Protagonist Therapeutics, Inc through 668 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years Protagonist Therapeutics, Inc's revenue grew from $20.06M to $46.02M, a compound annual growth rate of 10.9%. Net profit margin compressed from -184.2% to -282.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade (amended) | 4/A | 2026-05-14 |
| Insider sale notice | 144 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-07 |
| Insider sale notice | 144 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-05 |
The largest companies sharing Protagonist Therapeutics, Inc's SEC industry classification (pharmaceutical preparations).
Protagonist Therapeutics, Inc (PTGX) has a market capitalization of $6.80 B as of 2026-06-11, ranking #1171 among US-listed companies.
Protagonist Therapeutics, Inc reported revenue of $46.02M for fiscal year 2025, a decrease of 89.4% year over year.
In its latest fiscal year Protagonist Therapeutics, Inc reported a net loss of $130.15M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.